Photodynamic therapy and combination treatments

International Ophthalmology Clinics

Volumn 47, Issue 1, 2007, Pages 95-115

  Pachydaki, Sophia ^a   Sobrin, Lucia ^a   Miller, Joan W ^a  

^a MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; ETHYL ETIOPURPURIN; ETIOPURPURIN; LUTETIUM TEXAPHYRIN; PEGAPTANIB; PHOTOFRIN; PHOTOSENSITIZING AGENT; PLACEBO; PORPHYRIN DERIVATIVE; PROGESTERONE; PURLYTIN; RANIBIZUMAB; TRIAMCINOLONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANAPHYLAXIS; BLURRED VISION; CATARACT; CLINICAL TRIAL; DEPTH PERCEPTION; DYSPNEA; HUMAN; INJECTION SITE REACTION; INTRAOCULAR PRESSURE; LASER COAGULATION; MONOTHERAPY; NONHUMAN; PHOTODYNAMIC THERAPY; PHOTOSENSITIVITY; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; SYNCOPE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD DEFECT; VISUAL IMPAIRMENT;

ANIMALS; COMBINED MODALITY THERAPY; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; LASER COAGULATION; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TREATMENT OUTCOME;

EID: 33846422762     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31802bd7cf     Document Type: Review

References (58)

1. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in AMD. Arch Ophthalmol. 1991;109:1220-1231.
2. Weishaupt K, Gomer C, Dougherty T. Identification of singlet oxygen as the cytotoxic agent in photo-inactivation of murine tumor. Cancer Res. 1976;36:2326-2329.
3. Buettner G, Oberly L. The apparent production of superoxide and hydroxyl radicals by hematoporphyrin and light as seen by spin-trapping. Fed Biol Sci Lett. 1980;121:161-164.
4. Van Den Bergh HE. Principles of photodynamic therapy. In: Gragoudas E, Miller J, Zografos L, eds. Photodynamic Therapy of Ocular Diseases. Philadelphia: Lippincott Williams & Wilkins; 2004:1-9.
5. Fingar V. Vascular effect of photodynamic therapy. J Clin Laser Med Surg. 1996;14:323-328.
6. Peyman GA, Moshfeghi DM, Moshfeghi A, et al. PDT for choriocapillaris using etin ethyl etiopurpurin (SnET2). Ophthalmic Surg Lasers. 1997;28:409-417.
7. Thomas EL, Rosen R, Murphy RP, et al. SnET2 PDT produces closure of subfoveal choroidal neovascularization in humans. Invest Ophthalmol Vis Sci. 1998;39:S242.
8. Hunt DW. Rostaporfin (Miravant Medical Technologies). IDrugs. 2002;5:180-186.
9. Arbour J, Graham K, Carson D, et al. PDTof experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin. Invest Ophthalmol Vis Sci. 1999;40:S401.
10. Woodburn KW, Engelman CJ, Blumenkranz MS. PDT therapy for choroidal neovascularization: a review. Retina. 2002;22:391-405.
11. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumor model. Br J Cancer. 1991;63:87-93.
12. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol. 1995;113:810-818.
13. Husain D, Miller J, Michaud N, et al. Intravenous infusion using liposomal benzoporphyrin derivative verteporfin for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol. 1996;114:978-985.
14. Husain D, Kramer M, Kenney A, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroids up to seven weeks after treatment. Invest Ophthalmol Vis Sci. 1999;40:2322-2340.
15. Kramer M, Miller JW, Michaud N, et al. Liposomal BPD verteporfin PDT: selective treatment of choroidal neovascularization in monkeys. Ophthalmology. 1996;103:427-438.
16. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroids in the cynomologous monkey. Ophthalmology. 1999;106:1915-1923.
17. Miller J, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1161-1173.
18. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration. Results of a retreatment in a phase 1 and 2 study. Arch Ophthalmol. 1999;117:1177-1187.
19. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in AMD with verteporfin: one-year results of 2 randomized clinical trials - TAP report 1. Arch Ophthalmol. 1999;117:1329-1345.
20. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in AMD with verteporfin: two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol. 2001;119:198-207.
21. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in patients with AMD: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol. 2002;120:1443-1454.
22. Treatment of Age-Related Macular degeneration with Photodynamic Therapy (TAP) Study Group. Effects of Verteporfin therapy on contrast sensitivity: results from the Treatment of AMD with Photodynamic Therapy Investigation- TAP Report No.4. Retina. 2002;22:536-544.
23. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to AMD: TAP and VIP report 1. Am J Ophthalmol. 2003;136:407-418.
24. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy for subfoveal choroidal neovascularization in AMD: 3-year results of an open-label extension of 2 randomized clinical trials-TAP report 5. Arch Ophthalmol. 2002;120:1307-1314.
25. Kaiser PK. Treatment of AMD with Photodynamic Therapy (TAP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in AMD: 5-year results of two randomized clinical trials with an open-label extension TAP Rep No 8. Graefes Arch Clin Exp Ophthalmol. 2006;244:1132-1142.
26. Verteporfin in Photodynamic Therapy (VIP) Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a ranomized clinical trial including lesions with occult with no classic choroidal neovascularization-VIP report 2. Am J Ophthalmol. 2001;131:541-560.
27. Azab M, Boyer DS, Bressler NM, et al. Visudyne in Minimally Classic Choroidal Neovascularization Study Group. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in AMD: two-year results of a randomized clinical trial. Arch Ophthalmol. 2005;123:448-457.
28. Kaiser PK and the Verteporfin in Occult (VIO) Study Group. Verteporfin in Occult (VIO): the design of a phase III controlled clinical trial of verteporfin therapy for occult with no classic subfoveal choroidal neovascularization secondary to AMD. Invest Ophthalmol Vis Sci. 2004;45:E-Abstract 2276.
29. Stur M. Verteporfin Early Retreatment (VER) - 12-month results of a phase IIIb controlled clinical trial. Invest Ophthalmol Vis Sci. 2004;45:E-Abstract 2275.
30. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in AMD: meta-analysis of 2-year safety results in three randomized clinical trials: treatment of AMD with Photodynamic Therapy (TAP) and Verteporfin in Photodynamic Therapy Study (VIP) Report no. 4. Retina. 2004;24:1-12.
31. Arnold JJ, Blinder KJ, Bressler NM, et al,. Treatment of AMD with Photodynamic Therapy Study Group; Verteporfin in Photodynamic Therapy Study Group. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials-TAP and VIP report no 3. Am J Ophthalmol. 2004;137:683-696.
32. Doshi AB, Moshfeghi DM, Jack RL. Anaphylactoid reaction after verteporfin therapy. Am J Ophthalmol. 2005;140:936-937.
33. Cahill MT, Smith BT, Fekrat S. Adverse reaction characterized by chest pain, shortness of breath, and syncope associated with verteporfin. Am J Ophthalmol. 2002;134:281-282.
34. Bressler NM. VAM Study Writing Committee. Verteporfin therapy in AMD: an openlabel multicenter photodynamic therapy study of 4,435 patients. Retina. 2004;24:512-520.
35. Krzystolik MG, Afshari MA, Adamis AP, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol. 2002;120:338-346.
36. Kvanta A, Algreve P, Berglin L, et al. Subfoveal fibrovascular membranes in AMD express vascular endothelial growth factor. Invest Ophthalmol Vis Sci. 1996;37:1929-1934.
37. Kwak N, Okamoto N, Wood J, et al. VEGF is major stimulator in model of choroidal neovascularization. Invest Ophthalmol Vis Sci. 2000;41:3158-3164.
38. Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, et al. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmol. 2005;112:2061-2069.
39. Oh H, Takagi H, Tagaki C, et al. The potential angiogenic role of macrophages in the formation of choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1999;40:1891-1898.
40. Gollnick SO, Evans SS, Bauman H, et al. Role of cytokines in PDT-induced local and systemic inflammation. Br J Cancer. 2003;88:1772-1779.
41. Penfold PL, Wen L, Madigan MC, et al. Triamcinolone acetonide modulates permeability and intercellular adhesion molecule-1 (ICAM-1) expression of the ECV304 cell line implications for macular degeneration. Clin Exp Immunol. 2000;121:458-465.
42. Ciulla TA, Criswell MH, Danis RP, et al. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol. 2001;199:399-404.
43. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18 month follow up. Aust N Z J Ophthalmol. 1998;26:277-281.
44. Gillies MC, Simpson JM, Luo W, et al. A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular AMD: 1-year results. Arch Ophthalmol. 2003;121:667-673.
45. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization. Ophthalmol. 2003;110:1517-1525.
46. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmol. 2005;112:301-304.
47. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to AMD. Ophthalmology. 2006;113:14-22.
48. Rechtman E, Danis RP, Pratt LM, et al. Intravitreal triamcinolone with photodynamic therapy for subfoveal choroidal neovascularization in AMD. Br J Ophthalmol. 2004;88:344-347.
49. Spaide RF, Sorenson J, Maranan L. Combined photodynamic therapy and intravitreal triamcinolone acetonide for nonsubfoveal choroidal neovascularization. Retina. 2005;25:685-690.
50. Krebs I, Binder S, Stolba U. A new treatment regimen in combined intravitreal injection of triamcinolone acetonide and photodynamic therapy. Graefes Arch Clin Exp Ophthalmol. 2006;244:863-867.
51. Van de Moere A, Sandhu SS, Kak R, et al. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology. 2005;112:1896-1903.
52. Gragoudas ES, Adamis AP, Cummingham ET Jr, et al. Pegaptanib for age-related macular degeneration. N Eng J Med. 2004;351:2805-2816.
53. Kim IK, Husain D, Michaud N, et al. Effect of intravitreal injection of ranibizumab in combination with verteporfin PDT on normal primate retina and choroid. Invest Ophthalmol Vis Sci. 2006;47:357-363.
54. Husain D, Kim I, Michaud N, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol. 2005;123:509-516.
55. Funk M, Michels S, Wagner J, et al. Vascular effects of combined ranibizumab (Lucentis) and verteporfin (Visudyne) therapy in patients with neovascular AMD. Association for Research & Vision in Ophthalmology Annual Meeting, FL. 2006 No. B1020.
56. Schmidt-Erfurth UM, Gabel P, Hohman T, et al. Preliminary Results From an Open-Label, Multicenter, Phase II Study Assessing the Effects of Same-Day Andministration of Ranibizumab and Verteporfin PDT (PROTECT Study). Association for Research & Vision in Ophthalmology Annual Meeting, FL 2006, No. 2960.
57. Staurenghi G, Massacesi A, Musicco I, et al. Combining photodynamic therapy and feeder vessel photocoagulation: a pilot study. Semin Ophthalmol. 2001;16:233-236.
58. Piermarocchi S, Lo Giudice G, Sartore M, et al. Photodynamic therapy increases the eligibility for feeder vessel treatment of choroidal neovascularization caused by age-related macular degeneration. Am J Ophthalmol. 2002;133:572-575.